Provided by Tiger Trade Technology Pte. Ltd.

TG Therapeutics

54.30
+0.37000.69%
Pre-market: 54.300.00000.00%04:35 EDT
Volume:1.62M
Turnover:87.45M
Market Cap:8.31B
PE:19.61
High:54.36
Open:53.58
Low:52.67
Close:53.93
52wk High:59.30
52wk Low:26.76
Shares:153.09M
Float Shares:141.54M
Volume Ratio:1.01
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.77
EPS(LYR):2.77
ROE:100.28%
ROA:7.28%
PB:13.76
PE(LYR):19.60

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Toll Brothers, TG Therapeutics, CECO Environmental

Reuters
·
Jun 09

BUZZ-TG Therapeutics rises as early-stage data shows benefit in rare muscle weakness disease

Reuters
·
Jun 09

TG Therapeutics launches Phase 2 trial testing Briumvi maintenance after efgartigimod in myasthenia gravis

Reuters
·
Jun 09

TG Therapeutics - Subcutaneous Briumvi Generally Well Tolerated With Safety Profile Consistent With Iv Formulation

THOMSON REUTERS
·
Jun 09

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous Briumvi in Patients With Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

THOMSON REUTERS
·
Jun 09

TG Therapeutics - Initiates Phase 2 Trial of Briumvi as Maintenance Therapy After Efgartigimod Induction in Mg

THOMSON REUTERS
·
Jun 09

Analysts Offer Insights on Healthcare Companies: CVS Health (CVS), TG Therapeutics (TGTX) and Dexcom (DXCM)

TIPRANKS
·
Jun 04

B. Riley Securities Remains a Buy on TG Therapeutics (TGTX)

TIPRANKS
·
Jun 04

TG Therapeutics rises 10.6%

TIPRANKS
·
Jun 04

BUZZ-U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway

Reuters
·
Jun 03

Analysts’ Top Healthcare Picks: TG Therapeutics (TGTX), AbbVie (ABBV)

TIPRANKS
·
Jun 03

BUZZ-U.S. STOCKS ON THE MOVE-Ollie's Bargain Outlet Holdings, Steel Dynamics

Reuters
·
Jun 03

TG Therapeutics Reports Positive Phase 1 Data for Subcutaneous Multiple Sclerosis Therapy

MT Newswires Live
·
Jun 03

TG Therapeutics announces results from Briumvi trial

TIPRANKS
·
Jun 03

BUZZ-TG Therapeutics rises on positive early data for subcutaneous multiple sclerosis drug

Reuters
·
Jun 03

TG Therapeutics reports positive data for subcutaneous BRIUMVI

TIPRANKS
·
Jun 03

TG Therapeutics - Subcutaneous Briumvi Well-Tolerated With No New Safety Signals Observed

THOMSON REUTERS
·
Jun 03

TG Therapeutics Announces Positive Results From Phase 1 Trial Evaluating Subcutaneous Briumvi® (Ublituximab-Xiiy)

THOMSON REUTERS
·
Jun 03

TG Therapeutics - Topline Phase 3 Data for Subcutaneous Briumvi Expected Year-End 2026 or Early 2027

THOMSON REUTERS
·
Jun 03

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

GlobeNewswire
·
Jun 03